Polypeptide Therapy for Fast-Acting Allergic Conjunctivitis Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current clinical measures for allergic conjunctivitis, such as eye drops with antihistamines, mast cell stabilizers, glucocorticoids, and immunosuppressants, suffer from slow onset, limited efficacy, and potential ocular complications, leading to an unmet need for more effective treatments.

Innovation Solution

Administration of artificial polypeptides with specific amino acid sequences, such as those having at least 80% identity with SEQ ID NO: 1 or 2, to treat or prevent allergic conjunctivitis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antihistamines, mast cell stabilizers, glucocorticoids, and immunosuppressants are administered as eye drops, then allergic conjunctivitis symptoms are treated, but the onset is slow and efficacy is limited

Engineering Contradiction:

Improvetreatment efficacyVSAvoidonset speed

Core Design Contradiction:

ReliabilityVSSpeed

Solution Approach 1:

The patent changes the molecular parameters of the treatment by using polypeptides with specific amino acid sequences (at least 80% identity with SEQ ID NO: 1 or 2) instead of conventional small molecule drugs. This parameter change in molecular structure enables faster onset and improved efficacy while maintaining safety

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates artificial polypeptides that copy or mimic the structure and function of natural protective proteins (such as lactoferrin) found in the body. These copied structures provide rapid therapeutic effect by directly addressing the underlying immune response mechanism rather than merely blocking symptoms

Inventive Principle:

Principle #26Copying

2Object-affected harmful factors

If glucocorticoids and immunosuppressants are used to treat allergic conjunctivitis, then inflammation is reduced, but ocular complications may occur

Engineering Contradiction:

Improveinflammation reductionVSAvoidocular complications

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent converts the body's own immune response mechanism into a beneficial force by using polypeptides that modulate immunity rather than suppress it. The artificial polypeptides work with the immune system to reduce inflammation through natural regulatory pathways, transforming potential harm from immunosuppression into benefit from immune modulation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The artificial polypeptides act as intermediaries between the immune system and the allergen response. Instead of directly suppressing immune function with glucocorticoids, these polypeptide mediators regulate the immune response through specific receptor interactions, achieving anti-inflammatory effects without the harmful side effects of conventional immunosuppressants

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260070954A1Use of a polypeptide for the prevention or treatment of allergic conjunctivitis

Publication Date: 2026.03.12 SHANGHAI PUYOU BIOMEDICAL CO LTD

AI summary

The present disclosure provides use of a polypeptide for the prevention or treatment of allergic conjunctivitis. Also provided is a method for treating or preventing allergic conjunctivitis in a subject in need thereof, comprising administering to the subject an effective amount of any one of the polypeptides disclosed herein.